175 related articles for article (PubMed ID: 15221334)
21. Presence of glyceraldehyde-derived advanced glycation end-products in the liver of insulin-resistant mice.
Ebata Y; Takino J; Tsuchiya H; Sakabe T; Ikeda Y; Hama S; Kogure K; Takeuchi M; Shiota G
Int J Vitam Nutr Res; 2013; 83(2):137-41. PubMed ID: 24491887
[TBL] [Abstract][Full Text] [Related]
22. Glyceraldehyde-derived advanced glycation end-products preferentially induce VEGF expression and reduce GDNF expression in human astrocytes.
Miyajima H; Osanai M; Chiba H; Nishikiori N; Kojima T; Ohtsuka K; Sawada N
Biochem Biophys Res Commun; 2005 May; 330(2):361-6. PubMed ID: 15796891
[TBL] [Abstract][Full Text] [Related]
23. Formation mechanisms of melanoidins and fluorescent pyridinium compounds as advanced glycation end products.
Hayase F; Usui T; Ono Y; Shirahashi Y; Machida T; Ito T; Nishitani N; Shimohira K; Watanabe H
Ann N Y Acad Sci; 2008 Apr; 1126():53-8. PubMed ID: 18079473
[TBL] [Abstract][Full Text] [Related]
24. Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease.
Sato T; Shimogaito N; Wu X; Kikuchi S; Yamagishi S; Takeuchi M
Am J Alzheimers Dis Other Demen; 2006; 21(3):197-208. PubMed ID: 16869341
[TBL] [Abstract][Full Text] [Related]
25. Development of a monoclonal antibody-based ELISA system for glyceraldehyde-derived advanced glycation end products.
Matsui T; Joo HD; Lee JM; Ju SM; Tao WH; Higashimoto Y; Fukami K; Yamagishi S
Immunol Lett; 2015 Oct; 167(2):141-6. PubMed ID: 26304702
[TBL] [Abstract][Full Text] [Related]
26. Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes.
Unoki H; Bujo H; Yamagishi S; Takeuchi M; Imaizumi T; Saito Y
Diabetes Res Clin Pract; 2007 May; 76(2):236-44. PubMed ID: 17097186
[TBL] [Abstract][Full Text] [Related]
27. Decrease in the glyceraldehyde derived advanced glycation end products in the sera of patients with Vogt-Koyanagi-Harada disease.
Kitamura M; Kitaichi N; Takeuchi M; Kitamei H; Namba K; Yamagishi SI; Iwabuchi K; Onoé K; Ohno S
Br J Ophthalmol; 2005 Nov; 89(11):1407-9. PubMed ID: 16234440
[TBL] [Abstract][Full Text] [Related]
28. Advanced glycation end products as biomarkers and gerontotoxins - A basis to explore methylglyoxal-lowering agents for Alzheimer's disease?
Krautwald M; Münch G
Exp Gerontol; 2010 Oct; 45(10):744-51. PubMed ID: 20211718
[TBL] [Abstract][Full Text] [Related]
29. Intraneuronal amyloid-beta plays a role in mediating the synergistic pathological effects of apoE4 and environmental stimulation.
Levi O; Dolev I; Belinson H; Michaelson DM
J Neurochem; 2007 Nov; 103(3):1031-40. PubMed ID: 17666042
[TBL] [Abstract][Full Text] [Related]
30. 14-3-3 proteins and zeta isoform containing neurofibrillary tangles in patients with Alzheimer's disease.
Umahara T; Uchihara T; Tsuchiya K; Nakamura A; Iwamoto T; Ikeda K; Takasaki M
Acta Neuropathol; 2004 Oct; 108(4):279-86. PubMed ID: 15235803
[TBL] [Abstract][Full Text] [Related]
31. The formation of intracellular glyceraldehyde-derived advanced glycation end-products and cytotoxicity.
Takino J; Kobayashi Y; Takeuchi M
J Gastroenterol; 2010 Jun; 45(6):646-55. PubMed ID: 20084527
[TBL] [Abstract][Full Text] [Related]
32. A new insight on Al-maltolate-treated aged rabbit as Alzheimer's animal model.
Bharathi ; Shamasundar NM; Sathyanarayana Rao TS; Dhanunjaya Naidu M; Ravid R; Rao KS
Brain Res Rev; 2006 Sep; 52(2):275-92. PubMed ID: 16782202
[TBL] [Abstract][Full Text] [Related]
33. Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease.
Gouras GK; Almeida CG; Takahashi RH
Neurobiol Aging; 2005 Oct; 26(9):1235-44. PubMed ID: 16023263
[TBL] [Abstract][Full Text] [Related]
34. Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis.
Satoi H; Tomimoto H; Ohtani R; Kitano T; Kondo T; Watanabe M; Oka N; Akiguchi I; Furuya S; Hirabayashi Y; Okazaki T
Neuroscience; 2005; 130(3):657-66. PubMed ID: 15590150
[TBL] [Abstract][Full Text] [Related]
35. Altered subcellular location of phosphorylated Smads in Alzheimer's disease.
Ueberham U; Ueberham E; Gruschka H; Arendt T
Eur J Neurosci; 2006 Oct; 24(8):2327-34. PubMed ID: 17074053
[TBL] [Abstract][Full Text] [Related]
36. Advanced glycation end products impair glucose-induced insulin secretion from rat pancreatic β-cells.
Hachiya H; Miura Y; Inoue K; Park KH; Takeuchi M; Kubota K
J Hepatobiliary Pancreat Sci; 2014 Feb; 21(2):134-41. PubMed ID: 23798335
[TBL] [Abstract][Full Text] [Related]
37. Selective PrP-like protein, doppel immunoreactivity in dystrophic neurites of senile plaques in Alzheimer's disease.
Ferrer I; Freixas M; Blanco R; Carmona M; Puig B
Neuropathol Appl Neurobiol; 2004 Aug; 30(4):329-37. PubMed ID: 15305978
[TBL] [Abstract][Full Text] [Related]
38. Apolipoprotein D is a component of compact but not diffuse amyloid-beta plaques in Alzheimer's disease temporal cortex.
Desai PP; Ikonomovic MD; Abrahamson EE; Hamilton RL; Isanski BA; Hope CE; Klunk WE; DeKosky ST; Kamboh MI
Neurobiol Dis; 2005 Nov; 20(2):574-82. PubMed ID: 15916898
[TBL] [Abstract][Full Text] [Related]
39. Subcellular alteration of glyceraldehyde-3-phosphate dehydrogenase in Alzheimer's disease fibroblasts.
Mazzola JL; Sirover MA
J Neurosci Res; 2003 Jan; 71(2):279-85. PubMed ID: 12503091
[TBL] [Abstract][Full Text] [Related]
40. Detection of interleukin-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients.
Strauss S; Bauer J; Ganter U; Jonas U; Berger M; Volk B
Lab Invest; 1992 Feb; 66(2):223-30. PubMed ID: 1370967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
